{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:33:32Z","timestamp":1780608812161,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bioorg.2018.11.034","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:30:41Z","timestamp":1542864641000},"page":"211-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Evaluation of blood-brain barrier penetration and examination of binding to human serum albumin of 7-O-arylpiperazinylcoumarins as potential antipsychotic agents"],"prefix":"10.1016","volume":"84","author":[{"given":"Teresa","family":"\u017bo\u0142ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"D\u00f6m\u00f6t\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va A.","family":"Enyedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Maciejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9\u201310","key":"10.1016\/j.bioorg.2018.11.034_b0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","article-title":"Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival","volume":"17","author":"Morgan","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","article-title":"Strategies to advance translational research into brain barriers","volume":"7","author":"Neuwelt","year":"2008","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1152\/physrev.00035.2003","article-title":"Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis","volume":"84","author":"Bazzoni","year":"2004","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.bioorg.2018.11.034_b0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0035","first-page":"115","article-title":"Current in vitro and in silico models of blood-brain barrier penetration: a practical view","volume":"12","author":"Vastag","year":"2009","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"26","key":"10.1016\/j.bioorg.2018.11.034_b0040","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.2174\/092986708786242877","article-title":"A review of coumarin derivatives in pharmacotherapy of breast cancer","volume":"15","author":"Musa","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1568011053352550","article-title":"Synthetic and natural coumarins as cytotoxic agents","volume":"5","author":"Kostova","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.bioorg.2018.11.034_b0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejps.2017.08.036","article-title":"Theoretical evaluation of ADMET properties for coumarin derivatives as compounds with therapeutic potential","volume":"109","author":"\u017bo\u0142ek","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2018.11.034_b0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.phrs.2015.11.023","article-title":"Implication of coumarins towards central nervous system disorders","volume":"103","author":"Skalicka-Wozniak","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2018.11.034_b0060","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/jm400408r","article-title":"Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0960-894X(02)00933-2","article-title":"New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors","volume":"13","author":"Gonzalez-Gomez","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.11.034_b0070","first-page":"57","article-title":"Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles","volume":"8","author":"Kanazawa","year":"2015","journal-title":"Med. Dev. (Auckl.)"},{"issue":"23","key":"10.1016\/j.bioorg.2018.11.034_b0075","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1016\/j.bmcl.2011.09.100","article-title":"Synthesis of novel 3-carboxamide-benzocoumarin derivatives as orally active antithrombotic agents","volume":"21","author":"Sashidhara","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2018.11.034_b0080","first-page":"153","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv. Prot. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10895-007-0247-4","article-title":"Fluorescence study on the interaction of bovine serum albumin with p-aminoazobenzene","volume":"18","author":"Zhang","year":"2008","journal-title":"J. Fluoresc."},{"issue":"12","key":"10.1016\/j.bioorg.2018.11.034_b0090","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.bbagen.2013.05.005","article-title":"Albumin-drug interaction and its clinical implication","volume":"1830","author":"Yamasaki","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2018.11.034_b0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/jp012314u","article-title":"Interaction of ochratoxin a with human serum albumin. Preferential binding of the dianion and pH effects","volume":"106","author":"Il'ichev","year":"2002","journal-title":"J. Phys. Chem. B"},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0026-895X(25)14614-2","article-title":"Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone","volume":"21","author":"Fehske","year":"1982","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0105","first-page":"767","article-title":"Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied with albumin immobilized in microparticles","volume":"16","author":"Sjoholm","year":"1979","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0009-2797(95)03613-Q","article-title":"Binding of coumarins to site I of human serum albumin. Effect of the fatty acids","volume":"97","author":"Zaton","year":"1995","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2018.11.034_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2018.01.011","article-title":"Drug likeness prediction of 5-hydroxy-substituted coumarins with high affinity to 5-HT1A and 5-HT2A receptors","author":"\u017bolek","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(99)00130-1","article-title":"Study of heterocycle rings binding to human serum albumin","volume":"124","author":"Zaton","year":"2000","journal-title":"Chem.-Biol. Interact."},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.saa.2009.01.023","article-title":"Probing the binding of 8-Acetyl-7-hydroxycoumarin to human serum albumin by spectroscopic methods and molecular modeling","volume":"73","author":"Li","year":"2009","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.bioorg.2018.11.034_b0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejmech.2017.05.047","article-title":"Synthesis of a new series of aryl\/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT1A affinities","volume":"137","author":"Ostrowska","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.11.034_b0135","series-title":"Discovery Studio Modeling Environment, Release 2017","author":"Dassault Syst\u00e8mes BIOVIA","year":"2016"},{"key":"10.1016\/j.bioorg.2018.11.034_b0140","unstructured":"M.J. Frish, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, V.G. Zakrzewski, J.A.J. Montgomery, R.E. Stratmann, J.C. Burant, S. Dapprich, J.M. Millam, A.D. Daniels, K.N. Kudin, M.C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G.A. Petersson, P.Y. Ayala, Q. Cui, K. Morokuma, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J. Cioslowski, J.V. Ortiz, A.G. Baboul, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. Gomperts, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, C. Gonzalez, M.P. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, J.L. Andres, C. Gonzalez, M. Head-Gordon, E.S. Replogle, J.A. Pople, Gaussian, Inc., Pittsburgh, PA, 2009."},{"key":"10.1016\/j.bioorg.2018.11.034_b0145","unstructured":"ADMET PredictorTM Simulations Plus, Inc., Lancaster, California, USA."},{"key":"10.1016\/j.bioorg.2018.11.034_b0150","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2018.11.034_b0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"Charmm \u2013 a program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2018.11.034_b0160","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2018.11.034_b0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1103\/PhysRev.159.98","article-title":"Computer experiments on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules","volume":"159","author":"Verlet","year":"1967","journal-title":"Phys. Rev."},{"key":"10.1016\/j.bioorg.2018.11.034_b0170","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc Chem. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1432-1033.1974.tb03295.x","article-title":"A spectroscopic study of the haemin\u2013human-serum-albumin system","volume":"41","author":"Beaven","year":"1974","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bioorg.2018.11.034_b0180","series-title":"Computational Methods for the Determination of Formation Constants","first-page":"291","author":"Z\u00e9k\u00e1ny","year":"1985"},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00775-012-0944-6","article-title":"Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies","volume":"18","author":"Domotor","year":"2013","journal-title":"J. Biol. Inorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2018.11.034_b0190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1248\/bpb.24.935","article-title":"Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans","volume":"24","author":"Sakaeda","year":"2001","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/js980242l","article-title":"Hydrogen bonding. 47. Characterization of the ethylene glycol-heptane partition system: hydrogen bond acidity and basicity of peptides","volume":"88","author":"Abraham","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2018.11.034_b0200","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"10.1016\/j.bioorg.2018.11.034_b0205","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.bioorg.2018.11.034_b0210","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1023\/A:1015040217741","article-title":"Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs","volume":"16","author":"Kelder","year":"1999","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2018.11.034_b0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869808997889","article-title":"Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors","volume":"6","author":"van de Waterbeemd","year":"1998","journal-title":"J. Drug Target."},{"issue":"11","key":"10.1016\/j.bioorg.2018.11.034_b0220","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"10","key":"10.1016\/j.bioorg.2018.11.034_b0225","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2174\/1570180813666160622092839","article-title":"Analysis of the applicability and use of Lipinski's Rule for Central Nervous System Drugs","volume":"13","author":"Fernandes","year":"2016","journal-title":"Lett. Drug Des. Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cbpa.2008.03.019","article-title":"Blood-brain barrier permeability considerations for CNS-targeted compound library design","volume":"12","author":"Hitchcock","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2018.11.034_b0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002329900434","article-title":"Blood-brain barrier permeation: molecular parameters governing passive diffusion","volume":"165","author":"Fischer","year":"1998","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bioorg.2018.11.034_b0245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-0-387-44961-6_16","article-title":"Early preclinical evaluation of brain exposure in support of hit identification and lead optimization","volume":"4","author":"Raub","year":"2006","journal-title":"Biotechnol. Pharm. Asp"},{"issue":"1","key":"10.1016\/j.bioorg.2018.11.034_b0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.102.046532","article-title":"Inhibition of P-glycoprotein by newer antidepressants","volume":"305","author":"Weiss","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2018.11.034_b0255","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.190","article-title":"Chronic P-glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression","volume":"3","author":"O'Brien","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bioorg.2018.11.034_b0260","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1039\/tf9565201184","article-title":"Absorption and fluorescence spectra of coumarins","volume":"52","author":"Matto","year":"1956","journal-title":"Trans. Faraday Soc."},{"key":"10.1016\/j.bioorg.2018.11.034_b0265","series-title":"All About Albumin, Biochemistry, Genetics, and Medical Applications","author":"Peters","year":"1996"},{"issue":"3","key":"10.1016\/j.bioorg.2018.11.034_b0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Aspects Med."},{"issue":"6","key":"10.1016\/j.bioorg.2018.11.034_b0275","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0026-895X(25)10855-9","article-title":"Further characterization of specific drug binding sites on human serum albumin","volume":"12","author":"Sudlow","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2018.11.034_b0280","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bioorg.2013.10.003","article-title":"Interaction of anticancer reduced Schiff base coumarin derivatives with human serum albumin investigated by fluorescence quenching and molecular modeling","volume":"52","author":"Domotor","year":"2014","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2018.11.034_b0285","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1745-7254.2005.00068.x","article-title":"Predictive model of blood-brain barrier penetration of organic compounds","volume":"26","author":"Ma","year":"2005","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818311404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818311404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:00:30Z","timestamp":1775278830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206818311404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":57,"alternative-id":["S0045206818311404"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.11.034","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of blood-brain barrier penetration and examination of binding to human serum albumin of 7-O-arylpiperazinylcoumarins as potential antipsychotic agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}